Portolan Capital Management, LLC Zynerba Pharmaceuticals, Inc. Transaction History

Portolan Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$3.31 - $6.54 $1.44 Million - $2.84 Million	-434,768 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$2.9 - $6.16 $4,332 - $9,203	-1,494 Reduced 0.34%	434,768 $1.67 Million
Q4 2019 Feb 14, 2020	SELL	$5.61 - $8.57 $1.91 Million - $2.92 Million	-341,031 Reduced 43.87%	436,262 $2.64 Million
Q3 2019 Nov 14, 2019	BUY	$7.56 - $15.44 $1.14 Million - $2.32 Million	150,557 Added 24.02%	777,293 $5.88 Million
Q2 2019 Aug 14, 2019	BUY	$5.4 - $15.5 $3.38 Million - $9.71 Million	626,736 New	626,736 $8.49 Million

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Portolan Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Portolan Capital Management, LLC with notifications on news.